Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.50 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 4/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10844676 | 0.84 | KMT2A (0.43) | PDK1EP300HIF1ABACE1TDP1 | |
| SCHEMBL1340227 | 0.81 | TSHR (0.56) | PDK1CYP19A1ALDH1A1MAPTMAPK1 | |
| SCHEMBL28870755 | 0.81 | PDK1 (0.51) | PDK1EP300HIF1ACYP19A1TDP1 | |
| SCHEMBL224904 | 0.81 | ALDH1A1 (0.56) | BACE1EGFRTDP1ALDH1A1MAPT | |
| SCHEMBL1038678 | 0.80 | TDP1 (0.53) | PDK1EP300HIF1ACYP19A1TDP1 | |
| SCHEMBL28078625 | 0.80 | PDK1 (0.47) | PDK1EP300HIF1ACYP19A1TDP1 | |
| SCHEMBL17675377 | 0.80 | TDP1 (0.53) | PDK1EP300HIF1ACYP19A1TDP1 | |
| SCHEMBL29509060 | 0.80 | PDK1 (0.47) | PDK1EP300HIF1ACYP19A1TDP1 | |
| SCHEMBL7481571 | 0.80 | PDK1 (0.47) | PDK1EP300HIF1ACYP19A1TDP1 | |
| SCHEMBL6772017 | 0.80 | TSHR (0.53) | PDK1EP300HIF1ACYP19A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4477271-B1 | N-(PHENYL)-5-(HETEROARYL)-1H-PYRAZOL-3-AMINE DERIVATIVES AS TNIK INHIBITORS FOR USE IN THE TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4477271-A2 | COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | Korea Research Institute of Chemical Technology (KR) | 2024-12-18 | — | — | EP | disclosed |
| EP-3749648-B1 | N-(PHENYL)-5-(PHENYL)-1H-PYRAZOL-3-AMINE DERIVATIVES AS TNIK INHIBITORS FOR USE IN THE TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2024-10-30 | — | — | EP | disclosed |
| CN-111836801-B | Compounds for inhibiting TNIK and medical use thereof | 韩国化学硏究院 | 2024-02-02 | — | — | CN | disclosed |
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-09-26 | — | — | US | disclosed |
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-09-26 | — | — | US | disclosed |
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-09-26 | — | — | US | disclosed |
| US-20230039679-A1 | COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2023-02-09 | — | — | US | disclosed |
| US-20230039679-A1 | COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2023-02-09 | — | — | US | disclosed |
| US-11485711-B2 | Compounds for inhibiting TNIK and medical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-11-01 | — | — | US | disclosed |
| US-8673942-B2 | Fused ring compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8673942-B2 | Fused ring compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8673942-B2 | Fused ring compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-18 | — | — | US | disclosed |
| CN-102056924-A | Fused ring compounds and use thereof | TAKEDA PHARMACEUTICAL | 2011-05-11 | — | — | CN | disclosed |
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-28 | — | — | US | disclosed |
| EP-2276760-A1 | FUSED RING COMPOUNDS AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009125873-A1 | FUSED RING COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009125873-A1 | FUSED RING COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-15 | — | — | WO | disclosed |
| EP-0153642-A2 | Process for the preparation of monomeric aromatic hydroxyurethanes | BAYER AG (DE) | 1985-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | TNNI3K, TNK1, TNIK | PDK1 1971/4885EP300 1280/4885HIF1A 2926/4885 |
| US-11485711-B2 | Compounds for inhibiting TNIK and medical uses thereof | TNNI3K, TNK1, TNIK | PDK1 1971/4885EP300 1280/4885HIF1A 2926/4885 |
| US-20230039679-A1 | COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | TNNI3K, TNK1, TNIK | PDK1 1971/4885EP300 1280/4885HIF1A 2926/4885 |
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | GCKR, GPR119, SLC5A1 | PDK1 48/4885EP300 904/4885HIF1A 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.